biostudies-literatureUnknown3(10)Rooks D<h4>Importance</h4>The potential benefit of novel skeletal muscle anabolic agents to improve physical function in people with sarcopenia and other muscle wasting diseases is unknown.<h4>Objective</h4>To confirm the safety and efficacy of bimagrumab plus the new standard of care on skeletal muscle mass, strength, and physical function compared with standard of care alone in community-dwelling older adults with sarcopenia.<h4>Design, setting, and participants</h4>This double-blind, placebo-controlled, randomized clinical trial was conducted at 38 sites in 13 countries among community-dwelling men and women aged 70 years and older meeting gait speed and skeletal muscle criteria for sarcopenia. The study was conducted from December 2014 to June 2018, and analyses were conducted from August to JAMA network opene2020836https://www.ebi.ac.uk/biostudies/studies/S-EPMC7573681biostudies-literatureBimagrumab vs Optimized Standard of Care for Treatment of Sarcopenia in Community-Dwelling Older Adults: A Randomized Clinical Trial.PMC7573681Coleman LAPetricoul OVissing JRoubenoff RPerry RGRooks DChen LKChung YSPapanicolaou DAHemsley SPanchaud NFogarty CMLach-Trifilieff EPraestgaard JGoswami BMiller RRSwan TGarcia Garayoa ERecknor CLaurent DFilosa LABunte OHashimoto JArai HfalseBimagrumab vs Optimized Standard of Care for Treatment of Sarcopenia in Community-Dwelling Older Adults: A Randomized Clinical Trial.<h4>Importance</h4>The potential benefit of novel skeletal muscle anabolic agents to improve physical function in people with sarcopenia and other muscle wasting diseases is unknown.<h4>Objective</h4>To confirm the safety and efficacy of bimagrumab plus the new standard of care on skeletal muscle mass, strength, and physical function compared with standard of care alone in community-dwelling older adults with sarcopenia.<h4>Design, setting, and participants</h4>This double-blind, placebo-controlled, randomized clinical trial was conducted at 38 sites in 13 countries among community-dwelling men and women aged 70 years and older meeting gait speed and skeletal muscle criteria for sarcopenia. The study was conducted from December 2014 to June 2018, and analyses were conducted from August to 2020-01-01T00:00:00Z2020 Oct2026-05-03T22:22:40.816Z2020-10-29T12:32:44ZS-EPMC75736813307432710.1001/jamanetworkopen.2020.20836